Immunic announces publication of data from phase 1/1b clinical trial of imu-856 in the peer reviewed journal, the lancet gastroenterology & hepatology

–  includes phase 1 data in healthy human subjects and phase 1b data in celiac disease patients – new york , nov. 13, 2024 /prnewswire/ --  immunic, inc.  (nasdaq: imux), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that the data from its phase 1/1b clinical trial of imu-856, an orally available and systemically acting small molecule modulator that targets sirt6 (sirtuin 6), has been published in the peer reviewed journal, the lancet gastroenterology & hepatology. lead authored by dr. a.
IMUX Ratings Summary
IMUX Quant Ranking